The global pharmaceutical industry experienced a 33% decline in the number of immuno-oncology-related patent applications in Q2 2024 compared with the previous quarter. The total number of immuno-oncology-related grants dropped by 20% in Q2 2024, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q2 2024 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.
Notably, the number of immuno-oncology-related patent applications in the pharmaceutical industry was 338 in Q2 2024, versus 501 in the prior quarter.
The top five companies accounted for 15% of patenting activity
Analysis of patenting activity by companies shows that Immatics filed the most immuno-oncology patents within the pharmaceutical industry in Q2 2024. The company filed 21 immuno-oncology-related patents in the quarter, compared with 37 in the previous quarter. It was followed by University of Texas System with 11 immuno-oncology patent filings, Gilead Sciences (8 filings), and University of California (6 filings) in Q2 2024.
Patenting activity was driven by the US with a 62% share of total patent filings
The largest share of immuno-oncology related patent filings in the pharmaceutical industry in Q2 2024 was in the US with 62%, followed by Australia (6%) and China (4%). The share represented by the US was 13% higher than the 49% share it accounted for in Q1 2024.
For further understanding of GlobalData's Pharma: Patents Trends Q2 2024, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.